Drug Trial Radar · NCT05656027
Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
469
Actual
Start
Dec 19, 2022
Primary completion
Dec 15, 2023
Study completion Jan 25, 2024
Sponsor
- Lead sponsor
- LENZ Therapeutics, IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
Conditions
- Presbyopia
- Refractive Error
- Eye Diseases
- Near Vision
Interventions
Aceclidine+Brimonidine combination ophthalmic solutionDrug
LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
Aceclidine ophthalmic solutionDrug
LNZ100 Aceclidine ophthalmic solution
BrimonidineDrug
Brimonidine ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance VisionTime frame: 3 hours post-treatment in the study eye on Day 1
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Site #106
Chandler, Arizona
Site #121
Mesa, Arizona
Site #122
Phoenix, Arizona
Site #124
Phoenix, Arizona
Site #128
Scottsdale, Arizona
Site #125
Sun City, Arizona
Site #130
Azusa, California
Site #110
Garden Grove, California
Site #101
Glendale, California
Site #129
Newport Beach, California
Site #107
Petaluma, California
Site #126
Rancho Cordova, California
Site #111
Santa Barbara, California
Site #109
Littleton, Colorado
Site #102
Mt. Dora, Florida
Site #118
Rock Island, Illinois
Site #127
Overland Park, Kansas
Site #108
Pittsburg, Kansas
Site #131
Rochester, New York
Site #104
Fargo, North Dakota
Site #103
Kingston, Pennsylvania
Site #116
Memphis, Tennessee
Site #112
Smyrna, Tennessee
Site #119
San Antonio, Texas
Site #123
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.